Drug intelligence / Profile preview

GTI-889

Development stage: Preclinical
Lead developer: GSNO Therapeutics
Modality: Small Molecules

Overview

GTI-889 is a chemical drug candidate developed by GSNO Therapeutics. It is in preclinical development for the treatment of inflammation. The specific mechanism of action and molecular targets have not been publicly disclosed as of June 2025. Its primary therapeutic area is inflammation, but further details on its pharmacology or clinical data are not available[1][3].

Beyond the preview

Go deeper on GTI-889.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GTI-889.

Explore the full profile